Company
Developer of anti-inflammatory and wound-healing treatments from marine bioactive compounds
Broome, WA
Every investor coverage indicates participated in a round Marine Biomedical raised.
Companies Marine Biomedical acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Prof Minghao Zheng | Director | @AuManufacturing |
Stories naming Marine Biomedical. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Roundup of Australian manufacturing news: OncoSil, K-TIG and Aurora Labs complete or commit raises, Amplia opens an offer, Siemens agrees to buy Altair, CSIRO unveils a printed-solar facility, and a WA medical alliance grows.
Broome biotech Marine Biomedical opened a facility to make PearlBone, a synthetic bone substitute from oyster nacre, backed by a WA government grant, and plans regulatory submissions in Australia and the US.
Seven Kimberley projects share $773,000 in Western Australian government regional development grants, with Marine Biomedical receiving $200,000 toward a laboratory making its pearl-derived bone substitute PearlBone.